x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DMM-001112
| Status | Age | Sex |
|---|---|---|
|
|
|
| Product Overview | |
|---|---|
| Model Description | Cre-dependent SunTag-p65-HSF1 (SPH) transgenic mice were generated with piggyBac transposon system in F1 zygotes and crossed with wild type C57BL/6 mice. SPH transgenic mouse containing HA-tagged dCas9 fused with 10xGCN4, which is linked with p65-HSF1 and EGFP in tandem via P2A and T2A respectively. The transgene is driven by the ubiquitous CAG promoter and interrupted by a loxP-stop-loxP (LSL) cassette to render Cas9 expression inducible by the Cre recombinase. Expression of dCas9 can be detected using primary antibody: rabbit monoclonal antibody to HA-tag (1:1000, #3724, CST45) and secondary antibody: goat anti-rabbit Alexa Fluor 488 (1:1000, #A-11034, Thermo Fisher). |
| Strain Name | C57BL/6J-Tg(CAG-LSL-dCas9-SPH) |
| Background Strain | C57BL/6J |
| SPF | Yes |
| Research Application | Gene regulation tool; CRISPRa. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
